Nov. 13 at 2:18 PM
$VRAX almost a year old news...what's the update here?....
LONDON, Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today
announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland. "This agreement further strengthens our ongoing efforts to advance immune profiling technology and supports a growing need for comprehensive insights into immune health status through ImmuneSelect."
"We are honored to announce this agreement with Tebubio, who will prove to be instrumental in increasing the accessibility of ImmuneSelect for life science institutions across a crucial market such as Europe," said James Foster,
CEO of Virax Biolabs.
